GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US
Created by News on 4/1/2009 1:50:50 PM

GlaxoSmithKline (NYSE: GSK) today announced the submission of two simultaneous regulatory applications to expand the use of TYVERB(R)/TYKERB(R) (lapatinib). If approved, TYVERB(R)/TYKERB(R) could be used as a first-line therapy regimen combined with anti-hormonal therapy for patients with hormone-sensitive, metastatic (or advanced) breast cancer in Europe and the United States.


LONDON and PHILADELPHIA, April 1, /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced the submission of two simultaneous regulatory applications to expand the use of TYVERB(R)/TYKERB(R) (lapatinib). If approved, TYVERB(R)/TYKERB(R) could be used as a first-line therapy regimen combined with anti-hormonal therapy for patients with hormone-sensitive, metastatic (or advanced) breast cancer in Europe and the United States.

The variation to the EU marketing authorization and the supplemental New Drug Application (sNDA) were submitted respectively to the European Medicines Agency (EMEA) and to the U.S. Food and Drug Administration (FDA) for the combination of TYVERB/TYKERB plus an aromatase inhibitor based on the recent study, EGF30008. This study evaluated TYVERB/TYKERB in combination with letrozole in women whose breast cancer expressed was hormone receptor positive (HR+) and may or may not also over-expressed the HER2+/ErbB2+ receptor.

These data were presented at the San Antonio Breast Cancer Symposium in December 2008.

Breast cancer tumors which initially respond to anti-hormonal therapy such as letrozole can become resistant to treatment, leading to disease progression and ultimately, patient death.1 Between 60-70 percent of all breast cancer cases in Europe and the U.S. are HR+.2

"Tyverb/Tykerb with a hormone therapy is a biologically-rational targeted treatment, since the combination attacks two specific receptors that drive the cancer growth," said Debasish Roychowdhury , MD, Head, Medicines Development, GSK Oncology. "If approved the combination could provide a cytotoxic chemotherapy-free option for these patients and we look forward to working with regulatory agencies to advance the availability of this regimen as a new, oral option for patients in first-line breast cancer."

About TYVERB(R)/TYKERB(R) (lapatinib)

Lapatinib is an oral small-molecule inhibitor of the HER2/ErbB2 tyrosine kinase receptor. Stimulation of HER2/ErbB2 is associated with cell proliferation and with multiple processes involved in tumor progression and metastases. Overexpression of these receptors has been reported in a variety of human tumors and is associated with poor prognosis and reduced overall survival.

Lapatinib, in combination with capecitabine, is approved in 74 countries. On March 13, 2007, the U.S. FDA approved lapatinib in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2/ErbB2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. On June 10, 2008, the European Commission granted a conditional marketing authorization for lapatinib in all 27 European Union (EU) member states. Other countries in which lapatinib is approved for marketing include Australia, India, Brazil, Russia, Switzerland, Turkey, South Korea, Taiwan and others around the world. Registration dossiers for lapatinib have been filed in Canada, China, Japan, Mexico and a number of countries in Latin America, Middle East, Africa and Asia Pacific.

GSK in Oncology

GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK's revolutionary 'bench to bedside' approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector. Our worldwide research in oncology includes collaborations with more than 160 cancer centers. GSK is closing in on cancer from all sides with a new generation of patient-focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information please visit us.gsk.com

BOXED WARNING and Additional Important Safety Information for TYKERB

Hepatotoxicity - TYKERB has been associated with hepatotoxicity. Hepatotoxicity (ALT or AST >3 times the upper limit of normal and total bilirubin >1.5 times the upper limit of normal) has been observed in clinical trials (<1% of patients) and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain. The hepatotoxicity may occur days to several months after initiation of treatment. Liver function tests should be monitored before initiation of treatment, every 4 to 6 weeks during treatment, and as clinically indicated. If changes in liver function are severe, therapy with TYKERB should be discontinued and patients should not be re-treated with TYKERB.

Decreased Left Ventricular Ejection Fraction - TYKERB has been reported to decrease LVEF. Caution should be taken if TYKERB is to be administered to patients with preexisting cardiac conditions, including uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure. Confirm normal LVEF before starting TYKERB, and continue evaluations during treatment.

Patients with Severe Hepatic Impairment - If TYKERB is to be administered to patients with severe hepatic impairment, dose reduction should be considered.

Diarrhea - Diarrhea, including severe diarrhea, has been reported during treatment with TYKERB and was the most common adverse reaction resulting in discontinuation of TYKERB therapy. Proactive management of diarrhea with anti-diarrheal agents is important, and severe cases of diarrhea may require administration of oral or intravenous electrolytes and fluids, and interruption or discontinuation of therapy with TYKERB.

Interstitial Lung Disease/Pneumonitis - TYKERB has been associated with interstitial lung disease and pneumonitis. Patients should be monitored for pulmonary symptoms indicative of interstitial lung disease or pneumonitis and if symptoms are ¿ Grade 3 (NCI CTCAE), TYKERB should be discontinued.

QT Prolongation - TYKERB prolongs the QT interval in some patients. TYKERB should be administered with caution to patients who have or may develop prolongation of QTc. Hypokalemia or hypomagnesemia should be corrected prior to TYKERB administration. Baseline and on-treatment electrocardiograms with QT measurement should be considered.

Pregnancy: Pregnancy D - TYKERB can cause fetal harm when administered to a pregnant woman. Women should be advised not to become pregnant when taking TYKERB. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Adverse Reactions - The most common adverse reactions (>20%) during therapy with TYKERB plus capecitabine compared to capecitabine alone were diarrhea (65%, 40%), nausea (44%, 43%), vomiting (26%, 21%), palmar-plantar erythrodysesthesia (53%, 51%), rash (28%, 14%), and fatigue (46%, 47%).

The most common grade 3 and 4 adverse reaction (NCICTC v3) with TYKERB plus capecitabine compared to capecitabine alone were diarrhea (14%, 10%) and palmar-plantar erythrodysesthesia (12%, 14%).

Please see full prescribing information, including BOXED WARNING.

TYKERB(R) is a registered trademark of the GlaxoSmithKline group of companies in the United States and the countries outside of Europe.

TYVERB(R) is a registered trademark of the GlaxoSmithKline group of companies in European Union.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2008.

Registered in England & Wales:
No. 3888792

Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS

References

1 Prat, A and Baselga, J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nature Clinical Practice Oncology. 2008;5:531-542

2 Bedard PE, Freedman OC, Howell A et al. Overcoming endocrine resistance in breast cancer - are signal transduction inhibitors the answer. Breast Cancer Res Treat. 2008 108:307-317

print
The comment feature is locked by administrator.
Sort by:
profile photo
Lct3KX <a href="http://yzceaamkygcd.com/">yzceaamkygcd</a>
New Comment
By uskptrt on 4/22/2013 1:40:23 AM Like:-1 DisLike:-1
profile photo
HSBl73 , msjdnttrpide[/url], dnbmxbgzcref[/link], http://iysebrifhgmc.com/
New Comment
By xqvcrbezck on 4/20/2013 4:00:24 PM Like:-1 DisLike:-1
profile photo
zSHKEI , kjavtulqzrqd[/url], wlpvdcibzyum[/link], http://qpsxcrwgexuw.com/
New Comment
By gwawuszg on 4/20/2013 3:59:51 PM Like:-1 DisLike:-1
profile photo
RKsTXc , vfpauvwmafcp[/url], cqhgrpmozvlh[/link], http://nlcxaziruccq.com/
New Comment
By naxrsycnvqw on 4/20/2013 12:54:17 AM Like:-1 DisLike:-1
profile photo
What are the success fotracs in launching a new brand to J market? What are the key elements of marketing strategy? at the end, our brand message has to be understood by our customers and accepted and used by customers in a way we want them to do.The communication methods to our target audience are not so many. One is through our sales reps and the other, which I believe more efficient and influencial, is Dr to Dr communication. How to educate the top KOLs and have them talk about our new brand on our behalf is the most important aspect.Another which is indeed more difficult and time-consuming is the internal communications to convince our internal stakeholders that the strategy to dive into the market is correct and get them buy in our strategy/messages. This communication has to be ironically logical and precisely spoken in English with good communication and presentation capability. Here you may not be able to find many talents. But those who have good understanding of the market and how we can win the game in the competition are actually existing but only few of them speak good English and can explain the logic in a way the headquarters people understand.
New Comment
By Ayinde on 4/14/2013 6:54:55 AM Like:-1 DisLike:-1
profile photo
qolmZM <a href="http://ioxydasdahmv.com/">ioxydasdahmv</a>
New Comment
By gjhuvzun on 4/12/2013 10:01:51 AM Like:-1 DisLike:-1
profile photo
My sister-in- law had lasic suerrgy done in Colombia. The cost of the suerrgy, the air fare, and accommodations was less money than having the procedure done here in the United States..She claimed, and I believe, that there was nothing second rate in quality and care.
New Comment
By Sudhakarreddy on 4/12/2013 1:46:26 AM Like:-1 DisLike:-1
Search News
Top Stories

Apr24 Dental Health Products, Inc. (DHPI) Announces Strategic Alliance with the Dental Exchange
Created by Admin on 4/24/2015 9:24:38 AM

 Dental Health Products, Inc. (DHPI) and The Dental Exchange have announced the formation of a ne...
Read More..

Mar12 Dr. Richard Hughes Named an Honored Fellow of the American Academy of Implant Dentistry
Created by udent webmaster on 3/12/2015 11:04:13 AM

The American Academy of Implant Dentistry (AAID) has named Dr. Richard Hughes an Honored Fellow due ...
Read More..

Mar12 Deerfield Delivers Superior Veterinary Dentistry with Elite Drill
Created by udent webmaster on 3/12/2015 10:41:57 AM

One of Springfield’s leading animal hospitals continues its commitment to providing the best in vete...
Read More..

Mar12 Studio B Dental Launches New Website Specifically for Their All on 4 Dental Implant Procedure
Created by udent webmaster on 3/12/2015 10:39:47 AM

The new website launched by the popular Toronto dental clinic offers a simple 2 minute assessment fo...
Read More..

Mar09 Dr. E. Dale Behner Gives Indianapolis, IN Residents Access to a Minimally Invasive Receding Gums Treatment
Created by udent webmaster on 3/9/2015 10:09:50 PM

Dr. E. Dale Behner of Dental Care Today, PC is expanding his practice to offer help to those with re...
Read More..

Mar09 Growing Emphasis on Prevention of Caries Drives the Global Dental Preventive Supplies Market, According to a New Report by Global Industry Analysts, Inc
Created by udent webmaster on 3/9/2015 10:06:00 PM

Dental caries or tooth decay is one of the major issues for public healthcare systems in most countr...
Read More..

Mar07 Dr. John Schiro DDS Opens New Cosmetic Dentistry Practice in Austin, Texas
Created by udent webmaster on 3/7/2015 4:10:59 PM

Dr. John Schiro DDS is now announcing the grand opening of his new cosmetic dentistry practice in A...
Read More..

Mar20 One Third of Americans Still in Need of Affordable Dental Care Options
Created by Melissa Watkins on 3/20/2014 11:46:00 AM

According to Healthcare.gov, the Health and Human Services arm that is in charge of the federal heal...
Read More..

Feb11 DENTALPLANS.COM CREATES ONLINE PROJECT CENTER FOR NATIONAL CHILDREN’S DENTAL HEALTH MONTH
Created by Melissa Watkins on 2/11/2014 12:50:00 PM

 etting children to brush and floss every day isn’t always easy, especially when parents have a mil...
Read More..

Feb10 126.7 MILLION AMERICANS IN NEED OF DENTAL CARE OPTIONS
Created by Melissa Watkins on 2/10/2014 11:13:00 AM

 As the Affordable Care Act (ACA) discussion switches from accessing the federal and state health e...
Read More..

Jan21 DENTALPLANS.COM APPOINTS BOB HARRIS CHIEF EXECUTIVE OFFICER
Created by Melissa Watkins on 1/21/2014 3:39:00 PM

 entalPlans.com, a leading provider of dental savings plans, has named Bob Harris as chief executiv...
Read More..

Oct16 Keep Your Teeth White !
Created by Mint Cosmetics Review on 10/16/2013 11:58:00 PM

Great plastic is a teeth bleaching package which is prescribed by simply the majority of the dental ...
Read More..

Aug01 Gummy Smiles: What Are My Treatment Options?
Created by mapleavenuefamilydentistry on 8/1/2013 6:29:00 AM

When most people smile, you see a row of teeth that look beautiful and full. Unfortunately, this is ...
Read More..

Jul27 Plastic Surgeons Nj – A Smart Gateway To Beautification
Created by Dr. Michael A. Fiorillo, MD on 7/27/2013 12:05:00 AM

Plastic Surgeons Nj are veterans in the field of plastic surgery. These surgeons can completely cha...
Read More..

Jul22 Dental Implants: Evidence of Modern Dentistry
Created by paul589649 on 7/22/2013 4:50:00 AM

You can find out more about -   Dentist West Hartford CT , Dental Implants West Haven CT , De...
Read More..

Oct22 Guidance of Taking Good Care Of Braces
Created by bonniemendes on 10/22/2012 11:50:00 PM

 Guidance of Taking Good Care Of Braces Finding dependable techniques for taking care of braces as ...
Read More..

Aug13 Periodontist Comments On New Study Examining Diabetes Drug That May Be Able To Fight Oral Cancer
Created by Dr. Alex Farnoosh on 8/13/2012 12:24:00 PM

About The Total Smile: The Total Smile was founded by Beverly Hills Periodontist Dr. Alex Farn...
Read More..

Jul17 360imaging releases an improved version 4 of 360DPS dental implant planning software
Created by Manal on 7/17/2012 4:25:00 AM

 360 Imaging – an industry leader in dental implant planning - recently announced the release of  v...
Read More..

Jul11 iCare Financial Launches Strategic Alliance With Concorde Communications To Benefit Growth Of Dental Practices
Created by iCare Credit on 7/11/2012 4:28:00 PM

iCare Financial, a leading provider of patient credit, and Concorde Communications, an acclaimed me...
Read More..

Jun26 Periodontist Discusses Study Linking Osteoporosis Drug Complications To Patients With Certain Genes
Created by Dr. Alex Farnoosh on 6/26/2012 10:14:00 AM

On the heels of an earlier study linking antiresorptive drugs to medication induced osteonecrosis...
Read More..